CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CLD HEALTH OUTCOMES
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS)
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Embassy of Education CLDF Committees 2023 GI Fellow Board of Advisors
Embassy of Education
Publications Webcasts Algorithm Abstract Library Committee Members
 
HCC-Single Disease Content  
HCC Care Cascade Decision-Support Tool
 
Publications
 
Webcasts
HCC Epidemiology and Care Cascade Recommendations   Educational Webcast
New Advances in HCC Therapies   Educational Webcast
Slide Library
   Released: 2023
test
HCC Epidemiology and Care Cascade Recommendations
15 slides
 
 
   Released: 2022
test
New Advances in HCC Therapies
61 slides
 
 
   Released: 2021
test
Management and Treatment of HCC is Optimized in a Multidisciplinary Liver Tumor Board
61 slides
 
 
   Released: 2021
test
Sequence of Currently Approved Systemic Therapies for HCC: From First Line to Second Line and Beyond
53 slides
 
 
   Released: 2021
test
The Role of Precision Medicine in the Management and Treatment of HCC
33 slides
 
 
   Released: 2021
test
Integration of Immuno-Oncology to Improve HCC Outcomes: Immune Checkpoint Inhibition and Potential Synergies with Interventional Radiology and Radiation Oncology
30 slides
 
 
   Released: 2021
test
Non-Cirrhotic Risk Factors for HCC in Patients with NAFLD
35 slides
 
 
   Released: 2021
test
Recommendations to Optimize Surveillance of HCC
33 slides
 
 
   Released: 2021
test
Epidemiology and Surveillance for Hepatocellular Carcinoma
31 slides
 
 
   Released: 2021
test
Current Surgical Resection for Primary Liver Malignancies
87 slides
 
 
   Released: 2021
test
Second Line Therapies in HCC
30 slides
 
 
   Released: 2021
test
Thermal Ablation for HCC
96 slides
 
 
   Released: 2021
test
Transarterial Therapies for HCC: TACE and Y90
38 slides
 
 
   Released: 2021
test
Imaging of HCC Surveillance, Diagnosis, and Prognosis
38 slides
 
 
   Released: 2021
test
Update on the Front-Line Management of Advanced HCC
33 slides
 
 
   Released: 2021
test
Liver Transplantation for Patients with Hepatocellular Carcinoma
33 slides
 
 
   Released: 2021
test
HCC Research Update: From Bedside to Bench-side and Back to Bedside
26 slides
 
 
   Released: 2020
test
How to Approach HCV Treatment in Patients With HCC - DAA Before or After Liver Transplantation
40 slides
 
 
   Released: 2020
test
Down-Staging of Hepatocellular Carcinoma Before Liver Transplantation: Tumor Burden, Alpha-Fetoprotein and Wait Time Predict of Tumor Biology
45 slides
 
 
   Released: 2020
test
HCC Risk Biomarkers 2021: State of the Art and Future Perspective
65 slides
 
 
   Released: 2020
test
Novel Treatments and Emerging Targets for Hepatocellular Carcinoma (HCC)
52 slides
 
 
   Released: 2020
test
Surgical Options for Treatment of HCC - Resection vs. Liver Transplantation (LT)
74 slides
 
 
   Released: 2020
test
Interventional Oncology: Hepatocellular Carcinoma
63 slides
 
 
   Released: 2020
test
Update on HCC Clinical Trials: Barcelona HCC Criteria and Phase III Data
60 slides
 
 
   Released: 2020
test
Disparities in Linkage to Care for HCC
35 slides
 
 
   Released: 2020
test
HCC Surveillance in an Era of Biomarkers: Application of State-of-the-Art Tools
59 slides
 
 
   Released: 2020
test
Overview of Treatment Approaches to Hepatocellular Carcinoma
47 slides
 
 
   Released: 2020
test
Diagnosis and Staging of HCC
38 slides
 
 
   Released: 2020
test
Global HCC Trends: Implications for Prevention
54 slides
 
 
   Released: 2020
test
Changing Epidemiology of HCC in the U.S.
55 slides
 
 
   Released: 2020
test
Populations at High Risk for HCC in the U.S. - Implications for Clinical Practice
59 slides
 
 
   Released: 2019
test
Epidemiology HCC Innovations
21 slides
 
 
   Released: 2019
test
Intra-Arterial Therapies
25 slides
 
 
   Released: 2019
test
Immunotherapy for HCC and Emerging Treatments
72 slides
 
 
   Released: 2019
test
Liver Transplant for Hepatocellular Carcinoma
22 slides
 
 
   Released: 2019
test
Systemic Therapy for Liver Cancer
46 slides
 
 
   Released: 2019
test
Imaging and Biomarkers in HCC: Diagnosis and Surveillance
29 slides
 
 
   Released: 2019
test
Defining Outcomes of Hepatocellular Carcinoma therapy
51 slides
 
 
   Released: 2019
Webcast
Determining Hepatocellular Carcinoma Staging:Liver Disease Staging, Performance Status and RECIST Criteria
38 slides
 
 
   Released: 2019
Webcast
Surveillance for Hepatocellular Carcinoma
37 slides
 
 
   Released: 2018
test
Hepatology News Tonight: Managing Complication of Cirrhosis
57 slides
 
   
 
 
Abstract Library
1.Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals
 

Curr Opin Virol. 2024 Jun 25:67:101423. doi: 10.1016/j.coviro.2024.101423.Online ahead of print.

 

Felix Fiehn 1, Claudia Beisel 2, Marco Binder 3
 
2.Consensus statement on safety of combining transarterial radioembolization with 90yttrium microspheres with systemic anticancer agents for the treatment of liver malignancy
 

J Vasc Interv Radiol. 2024 Jun 15:S10510443(24)003981.doi:10.1016/j.jvir.2024.06.006. Online ahead of print.

 

Andrew S Kennedy 1, Daniel B Brown 2, Marwan Fakih 3, Rohan Jeyarajah 4, Suzanne Jones 5, David Liu 6, David J Pinato 7, Bruno Sangro 8, Navesh K Sharma 9, Daniel Y Sze 10, Eric Van Cutsem 11, Harpreet S Wasan 12
 
3.Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma
 

Liver Int. 2024 Jul;44(7):1588-1599. doi: 10.1111/liv.15855. Epub 2024 Mar 1.

 

Edoardo G Giannini 1 2, Andrea Pasta 1 2, Giulia Pieri 1 2, Maria Corina Plaz Torres 1 2, Mariarosaria Marseglia 3 4, Filippo Pelizzaro 5, Angelo Sangiovanni 6, Giuseppe Cabibbo 7, Giorgia Ghittoni 8, Mariella Di Marco 9, Francesco Giuseppe Foschi 10, Maria Guarino 11, Elisabetta Biasini 12, Carlo Saitta 13, Claudia Campani 14, Gianluca Svegliati-Baroni 15, Antonio Gasbarrini 16, Maurizia Rossana Brunetto 17, Donatella Magalotti 18, Francesco Azzaroli 19, Andrea Mega 20, Rodolfo Sacco 21, Gerardo Nardone 22, David Sacerdoti 23, Alberto Masotto 24, Gianpaolo Vidili 25, Laura Bucci 4 26, Alessandro Vitale 27, Franco Trevisani 4 26; Italian Liver Cancer (ITA.LI.CA) group

 

Collaborators

Italian Liver Cancer (ITA.LI.CA) group: 

Maurizio Biselli, Lorenzo Lani, Benedetta Stefanini, Valentina Santi, Alessandro Granito, Fabio Piscaglia, Francesco Tovoli, Luca Muratori, Francesca Benevento, Fabio Farinati, Gloria Allegrini, Calogero Cammà, Ciro Celsa, Paolo Giuffrida, Carmelo Marco Giacchetto, Gabriele Rancatore, Maria Vittoria Grassini, Roberta Ciccia, Alessandro Grova, Mauro Salvato, Valentina Adotti, Stefano Gitto, Fabio Marra, Martina Rosi, Vittoria Bevilacqua, Alberto Borghi, Fabio Conti, Anna Chiara Dall'Aglio, Giorgio Ercolani, Federica Mirici, Laura Schiadà, Chiara Scorzoni, Giulia Scandali, Francesca Romana Ponziani, Gabriele Missale, Andrea Olivani, Mario Capasso, Valentina Cossiga, Filomena Morisco, Ester Marina Cela, Antonio Facciorusso, Valentina Lauria, Giorgio Pelecca, Fabrizio Chegai, Fabio Coratella, Mariano Ortenzi, Serena Dell'Isola, Roberto Filomia, Concetta Pitrone, Giovanni Raimondo, Assunta Sauchella, Elton Dajti, Federico Ravaioli, Filippo Oliveri, Gabriele Ricco, Veronica Romagnoli, Alessandro Inno, Fabiana Marchetti, Pietro Coccoli, Antonio Malerba, Alberta Cappelli, Cristina Mosconi, Matteo Renzulli, Luca Marzi
 
4.HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States
 

Hepatology. 2024 Jun 19. doi: 10.1097/HEP.0000000000000953. Online ahead of print.

 

Hashem B El-Serag 1 2, Qingchun Jin 3, Tayob Nabihah 3, Emad Salem 1, Michelle Luster 1, Abeer Alsarraj 2, Saira Khaderi 1, Amit G Singal 4, Jorge A Marrero 5, Sumeet K Asrani 6, Fasiha Kanwal 1 2
 
5.Steatohepatitic Hepatocellular Carcinoma:A New Approach to Classifying Morphological Subtypes of Hepatocellular Carcinoma
 

Hum Pathol. 2024 Jun 12:S0046-8177(24)00108-4. doi: 10.1016/j.humpath.2024.06.007.Online ahead of print.

 

Gwyneth S T Soon 1, Francesco Callea 2, Alastair D Burt 3, Sam Cook 3, Luigi Terracciano 4, Caner Ercan 5, Hans-Peter Dienes 6, Zachary D Goodman 7, Eve A Roberts 8, Andrew D Clouston 9, Annette S H Gouw 10, David E Kleiner 11, Young Nyun Park 12, Taek Chung 13, Peter Schirmacher 14, Dina Tiniakos 15, Konstantina Dimopoulou 16, Achim Weber 17, Katharina Endhardt 17, Michael Torbenson 18
 
6.A Meta-Analysis of Cumulative Incidence of Hepatocellular Carcinoma After the Fontan Operation
 

Dig Dis Sci. 2024 Jun 13. doi: 10.1007/s10620-024-08470-1. Online ahead of print.

 

Sophie Hansen 1 2, Richard Gilroy 2, Ian Lindsay 3, John R Doty 4, Ross A Butschek 5, Christopher J Danford 6
 
7.Is home-based, virtually delivered, group exercise feasible and acceptable for older patients with hepatocellular carcinoma? A non-randomised feasibility study (TELEX-Liver Cancer)
 

BMJ Open. 2024 Jun 12;14(6):e082155. doi: 10.1136/bmjopen-2023-082155.

 

Kate Hallsworth 1 2 3, Misti V McCain 4 3 5, Roisin Fallen-Bailey 6, Morven C Brown 5 7, Samuel T Orange 4 5 7 8, Helen L Reeves 4 2 3 5
 
8.Tumor Mutational Burden from Circulating Tumor DNA Predicts Recurrence of Hepatocellular Carcinoma After Resection: An Emerging Biomarker for Surveillance: An Emerging Biomarker for Surveillance
 

Ann Surg. 2024 Jun 11. doi: 10.1097/SLA.0000000000006386. Online ahead of print.

 

Chase J Wehrle 1, Hanna Hong 1, Suneel Kamath 2, Andrea Schlegel 1, Masato Fujiki 1, Koji Hashimoto 1, David Choon Hyuck Kwon 1, Charles Miller 1, R Matthew Walsh 1, Federico Aucejo 1
 
9.EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary
 

Diabetologia. 2024 Jun 13. doi: 10.1007/s00125-024-06196-3. Online ahead of print.

 

European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity; Clinical Practice Guideline Panel
 
10.Combination and Optimal Sequencing of Systemic and Locoregional Therapies in Hepatocellular Carcinoma: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel
 

J Vasc Interv Radiol. 2024 Jun;35(6):818-824. doi: 10.1016/j.jvir.2024.02.017.

 

Lindsay M Thornton 1, Nadine Abi-Jaoudeh 2, Howard J Lim 3, Katerina Malagari 4, Benjamin Oren Spieler 5, Masatoshi Kudo 6, Richard S Finn 7, Riccardo Lencioni 8, Sarah B White 9, Nima Kokabi 10, D Rohan Jeyarajah 11, Prosanto Chaudhury 12, David Liu 13
 
11.Safety and tolerability of radiotherapy in combination with systemic targeted therapies for treatment of hepatocellular carcinoma: a narrative review
 

Chin Clin Oncol. 2024 May 19:cco-23-140. doi: 10.21037/cco-23-140. Online ahead of print.

 

Madeleine L Hall 1, Sweet Ping Ng 2, Umbreen Hafeez 3, Niall Tebbutt 4, Marie Sinclair 5, Farshad Foroudi 6, Michael Chao 6, Richard Khor 6
 
12.Interventional radiology meets immuno-oncology for hepatocellular carcinoma
 

J Hepatol. 2024 Jun;80(6):967-976. doi: 10.1016/j.jhep.2022.08.003.Epub 2022 Aug 19.

 

Riad Salem 1, Tim F Greten 2
 
13.Metformin as adjuvant treatment in hepatitis C virus infections and associated complications
 

Am J Med Sci. 2024 May 1:S0002-9629(24)01213-8.doi: 10.1016/j.amjms.2024.04.019. Online ahead of print.

 

Dylan Landis 1, Alex Sutter 1, Sachi Khemka 1, Busara Songtanin 1, Jacob Nichols 1, Kenneth Nugent 2
 
14.Statewide Survey of Primary Care and Subspecialty Providers on Hepatocellular Carcinoma Risk-Stratification and Surveillance Practices
 

Dig Dis Sci. 2024 Apr 23. doi: 10.1007/s10620-024-08442-5. Online ahead of print.

 

Andrew M Moon 1 2 3, Rachel M Swier 4, Lindsay M Lane 5, A Sidney Barritt 4th 6 7, Hanna K Sanoff 8 9, Andrew F Olshan 10, Stephanie B Wheeler 8 11, George N Ioannou 12 13, Nicole J Kim 13, Scott Hagan 14, Philip Vutien 13, Thad Benefield 5, Louise M Henderson 8 5 10
 
15.Clinical outcomes of hepatocellular carcinoma surveillance in Melbourne, Australia
 

Intern Med J. 2024 Apr 26. doi: 10.1111/imj.16405. Online ahead of print.

 

Samuel Hui 1 2, Andrew Nguyen 2, Suong Le 1 2, Anouk Dev 1 2, Sally Bell 1 2
 
16.Natural History of Indeterminate Liver Nodules in Patients with Advanced Liver Disease: A Multi-Center Retrospective Cohort Study
 

Am J Gastroenterol. 2024 Apr 30. doi: 10.14309/ajg.0000000000002827. Online ahead of print.

 

Amit G Singal 1, Neehar D Parikh, Kirti Shetty, Steven-Huy Han, Cassie Xie, Jing Ning, Jo Ann Rinaudo, Ashwini Arvind, Anna S Lok, Fasiha Kanwal; Translational Liver Cancer Investigators
 
17.Acute hepatic porphyrias - a guide for Hepatologists
 

Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000880. Online ahead of print.

 

Akshata Moghe 1, Brendan M McGuire 2, Cynthia Levy 3
 
18.Case-based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management
 

Liver Int. 2024 Apr 15. doi: 10.1111/liv.15924. Online ahead of print.

 

Manisha Balwani 1, Siobán Keel 2, Peter Meissner 3, Mark Sonderup 4, Penelope Stein 5, Makiko Yasuda 1
 
19.Local recurrence following a complete radiologic response in hepatocellular carcinoma patients: comparison of transarterial chemoembolisation and transarterial radioembolization
 

Clin Radiol. 2024 May;79(5):371-377. doi: 10.1016/j.crad.2024.01.014. Epub 2024 Jan 29.

 

S Young 1, T Sanghvi 2, R Ragulojan 3, P Torkian 3, S Todatry 3, D D'Souza 3, S Flanagan 3, J Golzarian 3
 
20.Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
 

J Clin Oncol. 2024 Mar 19:JCO2302745. doi: 10.1200/JCO.23.02745. Online ahead of print.

 

John D Gordan 1, Erin B Kennedy 2, Ghassan K Abou-Alfa 3 4, Eliza Beal 5, Richard S Finn 6, Terence P Gade 7, Laura Goff 8, Shilpi Gupta 9, Jennifer Guy 10, Hang T Hoang 11, Renuka Iyer 12, Ishmael Jaiyesimi 13, Minaxi Jhawer 14, Asha Karippot 15, Ahmed O Kaseb 16, R Kate Kelley 1, Jeremy Kortmansky 17, Andrea Leaf 18, William M Remak 19, Davendra P S Sohal 20, Tamar H Taddei 21, Andrea Wilson Woods 22, Mark Yarchoan 23, Michal G Rose 24
 
21.Routes to diagnosis for hepatocellular carcinoma patients: predictors and associations with treatment and mortality
 

Br J Cancer. 2024 Mar 18. doi: 10.1038/s41416-024-02645-3. Online ahead of print.

 

Anya Burton 1 2, Jennifer Wilburn 3, Robert J Driver 4, David Wallace 5 6, Sean McPhail 3, Tim J S Cross 7, Ian A Rowe 4, Aileen Marshall 8
 
22.Mechanisms of drug resistance in HCC
 

Hepatology. 2024 Apr 1;79(4):926-940. doi: 10.1097/HEP.0000000000000237.Epub 2023 Jan 3.

 

Alexandra D Ladd 1, Sergio Duarte 1, Ilyas Sahin 2, Ali Zarrinpar 1
 
23.Implementation of a National Liver Review Board for exception requests in the United States: A 2-year monitoring report
 

Liver Transpl. 2024 Apr 1;30(4):367-375. doi: 10.1097/LVT.0000000000000248.Epub 2023 Aug 29.

 

Allison J Kwong 1, Julia Foutz 2, Matt Cafarella 2, Scott W Biggins 3, Neil D Shah 4, James Eason 5, Emily R Perito 6, James Pomposelli 7, James Trotter 8
 
24.a-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
 

Int J Cancer. 2024 Mar 15;154(6):1043-1056. doi: 10.1002/ijc.34799. Epub 2023 Nov 23.

Federico Rossari 1 2, Toshifumi Tada 3, Goki Suda 4, Shigeo Shimose 5, Masatoshi Kudo 6, Changhoon Yoo 7, Jaekyung Cheon 8, Fabian Finkelmeier 9, Ho Yeong Lim 10, José Presa 11, Gianluca Masi 12 13, Francesca Bergamo 14, Elisabeth Amadeo 1, Francesco Vitiello 1, Takashi Kumada 15, Naoya Sakamoto 4, Hideki Iwamoto 5, Tomoko Aoki 6, Hong Jae Chon 8, Vera Himmelsbach 9, Massimo Iavarone 16, Giuseppe Cabibbo 17, Margarida Montes 11, Francesco Giuseppe Foschi 18, Caterina Vivaldi 12 13, Caterina Soldà 14, Takuya Sho 4, Takashi Niizeki 5, Naoshi Nishida 6, Christoph Steup 9, Masashi Hirooka 19, Kazuya Kariyama 20, Joji Tani 21, Masanori Atsukawa 22, Koichi Takaguchi 23, Ei Itobayashi 24, Shinya Fukunishi 25, Kunihiko Tsuji 26, Toru Ishikawa 27, Kazuto Tajiri 28, Hironori Ochi 29, Satoshi Yasuda 30, Hidenori Toyoda 30, Chikara Ogawa 31, Takashi Nishimura 32, Takeshi Hatanaka 33, Satoru Kakizaki 34, Noritomo Shimada 35, Kazuhito Kawata 36, Atsushi Hiraoka 37, Fujimasa Tada 37, Hideko Ohama 37, Kazuhiro Nouso 20, Asahiro Morishita 21, Akemi Tsutsui 23, Takuya Nagano 23, Norio Itokawa 22, Tomomi Okubo 22, Michitaka Imai 27, Hisashi Kosaka 38, Atsushi Naganuma 39, Yohei Koizumi 
 
25.Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy
 

J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16501. Online ahead of print.

 

N M Batt 1, B Rodrigues 1, S Bloom 1 2, R Sawhney 1 2, E S George 3, A Hodge 1 2, N Vootukuru 1, C McCrae 1, Surbhi Sood 3, S K Roberts 4 5, A Dev 6, S Bell 5 6, A Thompson 7 8, M C Ryan 7 8, W Kemp 4, P J Gow 9, Siddharth Sood 10, A J Nicoll 1 2
 
View More
 
 
 

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

NASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2024 GI Fellow Board of Advisors

Other Resources

Journal Abstracts

Subscribe

Be the first to know about our latest upcoming programs and events!
CLDF

Follow us
Facebook
Twitter
Youtube
LiverQ
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2024 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.